Abstract 247P
Background
To determine the p53 gene suppressor and bcl-2 oncoprotein forecast role in non-epithelial ovarian tumor prognosis among child and adolescent patients.
Methods
Our search is based on immunohistochemical method results of 35 patients with non-epithelial ovarian tumors at I-IV stages, which were diagnosed and treated in oncogynecology and children oncology departments .
Results
The analysis of immunohistochemical method results shows 7(20%) patients among which had been marked high expression bcl-2 oncoprotein, 11(31,4%) moderate express, 16(45,7%) low express. Analysis of p53 gene suppressor results shows 9(25,7%) patients among which had been marked high expression, 11(31,4%) moderate express, 15(42,8%) low express. The high correlation between bcl-2 expression level increases and fast tumor growth, and therefore incurability of oncologic process among of patients had been revealed. Also the high probability of tumor recurrence was noticed. In the high-positive p53 gene suppressor rate group took place aggressive current of tumor process and these patients had early recurrence and metastases, which demanded recurrent aggressive chemotherapy
Conclusions
p53 gene suppressor and bcl-2 oncoprotein expression in non-epithelial ovarian tumors among the child and adolescent patients is characterized with high and low rates, which enables to use this rate determination for given pathology currency prognosis identification.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session